Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

被引:179
|
作者
Lugthart, Sanne
Groschel, Stefan
Beverloo, H. Berna
Kayser, Sabine
Valk, Peter J. M.
van Zelderen-Bhola, Shama Lydia
Ossenkoppele, Gert Jan
Vellenga, Edo
van den Berg-de Ruiter, Eva
Schanz, Urs
Verhoef, Gregor
Vandenberghe, Peter
Ferrant, Augustin
Kohne, Claus-Henning
Pfreundschuh, Michael
Horst, Heinz A.
Koller, Elisabeth
von Lilienfeld-Toal, Marie
Bentz, Martin
Ganser, Arnold
Schlegelberger, Brigitte
Jotterand, Martine
Krauter, Jurgen
Pabst, Thomas
Theobald, Matthias
Schlenk, Richard F.
Delwel, Ruud
Dohner, Konstanze
Lowenberg, Bob
Doehner, Hartmut [1 ]
机构
[1] Univ Hosp, Dept Internal Med 3, Ulm, Germany
关键词
BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; ADULT PATIENTS; CYTOGENETIC ABNORMALITIES; POSTREMISSION THERAPY; NORMAL-TISSUES; EXPRESSION; DIAGNOSIS; CANCER;
D O I
10.1200/JCO.2010.29.2771
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3; 3)(q21; q26.2) inv(3)/t(3; 3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3; 3) remain largely unresolved. Patients and Methods Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian HematoOncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction. Results 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3; 3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3; 3). Patients with inv(3)/t(3; 3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3; 3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P<.001) and overall survival (HR, 1.4; P=.006). This adverse prognostic impact of inv(3)/t(3; 3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3; 3). Conclusion Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3; 3) represents a distinctive subgroup with unfavorable prognosis.
引用
收藏
页码:3890 / 3898
页数:9
相关论文
共 50 条
  • [1] Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML
    Groeschel, S.
    Lugthart, S.
    Beverloo, B. H.
    Kayser, S.
    Valk, P. J.
    Van Zelderen-Bhola, S. L.
    Ossenkoppele, G-J
    Vellenga, E.
    van den Berg-de Ruiter, E.
    Schanz, U.
    Verhoef, G.
    Ferrant, A.
    Koehne, C-H
    Pfreundschuh, M.
    Horst, H-A
    Koller, E.
    von Lilienfeld-Toal, M.
    Bentz, M.
    Ganser, A.
    Schlegelberger, B.
    Jotterand, M.
    Krauter, J.
    Pabst, T.
    Theobald, M.
    Schlenk, R. F.
    Delwel, R.
    Doehner, K.
    Lowenberg, B.
    Doehner, H.
    ONKOLOGIE, 2010, 33 : 6 - 6
  • [2] Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
    Medeiros, Bruno C.
    Kohrt, Holbrook E.
    Arber, Daniel A.
    Bangs, Charles D.
    Cherry, Athena M.
    Majeti, Ravindra
    Kogel, Karen E.
    Azar, Catherine A.
    Patel, Samit
    Alizadeh, Ash A.
    LEUKEMIA RESEARCH, 2010, 34 (05) : 594 - 597
  • [3] Myelodysplastic syndromes and acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) abnormality
    Calderon-Cabrera, Cristina
    Falantes, Jose F.
    Bernal, Ricardo
    Perez-Simon, Jose A.
    MEDICINA CLINICA, 2015, 145 (05): : 224 - 226
  • [4] Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
    Richard-Carpentier, Guillaume
    Rausch, Caitlin R.
    Sasaki, Koji
    Hammond, Danielle
    Morita, Kiyomi
    Takahashi, Koichi
    Tang, Guilin
    Kanagal-Shamanna, Rashmi
    Bhalla, Kapil
    Dinardo, Courtney D.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Shpall, Elizabeth J.
    Alousi, Amin
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Konopleva, Marina Y.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    HAEMATOLOGICA, 2023, 108 (09) : 2331 - 2342
  • [5] Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
    Richard-Carpentier, Guillaume
    Rausch, Caitlin R.
    Sasaki, Koji
    Hammond, Danielle
    Morita, Kiyomi
    Takahashi, Koichi
    Tang, Guilin
    Kanagal-Shamanna, Rashmi
    Bhalla, Kapil
    Dinardo, Courtney D.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Shpall, Elizabeth J.
    Alousi, Amin
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Konopleva, Marina Y.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    REVISTA CHILENA DE LITERATURA, 2023, (108): : 2331 - 2342
  • [6] Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study
    Gong, Xubo
    Yu, Teng
    Tang, Qiusu
    Fu, Yanbiao
    Wu, Jie
    Zhu, Yongze
    Tu, Hongxiang
    Ge, Haifeng
    Lu, Xingguo
    Gong, Donghua
    Zhao, Xiaoying
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (03) : 380 - 386
  • [7] A Variant of Inv(3)(q21q26.2) or t(3;3)(q21;q26.2) (MECOM) Rearrangement in AML
    Mueller, Rosemary
    Wong, Olivia
    Cancer Genetics, 2016, 209 (05) : 244 - 244
  • [8] A STUDY ON THE CLINICAL SIGNIFICANCE OF THE WHO AML SUBTYPE INV(3)(Q21Q26.2)/T(3;3)(Q21;Q26.2) AND VARIOUS OTHER 3Q CHROMOSOMAL ABNORMALITIES IN 6,819 AML CASES
    Lugthart, S.
    Groeschel, S.
    Beverloo, H.
    Valk, P.
    Schanz, U.
    Bhola, S.
    Vellenga, E.
    Kayser, S.
    Ossenkoppele, G.
    Verhoef, G.
    Ferrant, A.
    van den Berg-de Ruiter, E.
    Ganser, A.
    Jotterand, M.
    Krauter, J.
    Pabst, T.
    Schlegelberger, B.
    Schlenk, R.
    Delwel, R.
    Doehner, K.
    Loewenberg, B.
    Doehner, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 482 - 482
  • [9] Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups
    Sitges, M.
    Boluda, B.
    Garrido, A.
    Morgades, M.
    Arnan, M.
    Serrano, J.
    Tormo, M.
    Colorado, M.
    Bergua, J. M.
    Salamero, O.
    Esteve, J.
    Benavente, C.
    Perez-Encinas, M.
    Coll, R.
    Marti-Tutusaus, J. M. M.
    Ribera, J. M.
    Brunet, S.
    Sierra, J.
    Sanz, M. A.
    Montesinos, P.
    Vives, S.
    ANNALS OF HEMATOLOGY, 2019, 98 : S42 - S42
  • [10] Myelodysplastic Syndrome With inv(3)(q21q26.2) or t(3;3)(q21;q26.2) Has a High Risk for Progression to Acute Myeloid Leukemia
    Cui, Wei
    Sun, Jianlan
    Cotta, Claudiu V.
    Medeiros, L. Jeffrey
    Lin, Pei
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 136 (02) : 282 - 288